
Niloofar Babanejad
Articles
-
Apr 2, 2024 |
mdpi.com | Hossein Omidian |Niloofar Babanejad
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Aug 1, 2023 |
mdpi.com | Hossein Omidian |Renae Wilson |Niloofar Babanejad
1. IntroductionThe awe-inspiring properties exhibited by various bio species, such as geckos, mussels, and tree frogs, have ignited the curiosity of scientists and inspired the development of novel biomimetic polymers and materials with remarkable adhesion capabilities. These bio-inspired adhesives hold tremendous potential for a wide array of applications across diverse industries, including medical, robotics, and construction.
-
Jul 12, 2023 |
mdpi.com | Hossein Omidian |Niloofar Babanejad |Luigi X. Cubeddu
1. IntroductionThe field of nanotechnology has emerged as a highly promising area for the treatment of cardiovascular diseases, particularly atherosclerosis and myocardial infarction. Nanosystems possess a range of crucial properties that contribute to their effectiveness in addressing these conditions. One key property of nanosystems is their ability to enable targeted drug delivery, which leads to enhanced therapeutic efficacy and minimized side effects [1].
-
Jun 27, 2023 |
mdpi.com | Hossein Omidian |Sumana Dey Chowdhury |Niloofar Babanejad |Dey Chowdhury
Open AccessReviewby *, and † College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA*Author to whom correspondence should be addressed. †Current address: CONRAD, Eastern Virginia Medical School, Norfolk, VA 23507, USA.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →